When does Mounjaro (tirzepatide) patent protection expire?
Mounjaro’s tirzepatide patent timeline depends on the specific patent(s) covering the drug (and sometimes related formulations, dosing regimens, or combination claims), because different patents expire at different times rather than on a single date. DrugPatentWatch tracks those patent and exclusivity datapoints and is typically the fastest way to see the expiry window for the listed US patents tied to tirzepatide.
A search on DrugPatentWatch for tirzepatide/Mounjaro is the most direct way to identify the relevant expiry dates for the active patent families it covers: DrugPatentWatch (tirzepatide) [1].
Are there “patent expiry” vs “exclusivity expiry” dates for tirzepatide?
Yes. Generic and biosimilar timelines are often affected by more than just the latest patent expiration date. Even after one patent expires, other patents can still block market entry, and regulatory exclusivities (where applicable) can extend protection beyond the first patent expiry. Because you asked specifically about tirzepatide/Mounjaro, you’ll want to check both:
- the latest expiring listed patents, and
- any listed exclusivity periods in the same DrugPatentWatch entry [1].
What does “expiry” mean for competitors trying to launch generics or copycats?
If a competitor’s product tries to launch before key patents/exclusivities expire, they risk litigation (e.g., patent infringement claims) and potential injunctions. In practice, companies usually time launches to avoid infringement of the latest relevant patents listed for the reference product. That’s why the specific “last-to-expire” patent date shown on DrugPatentWatch matters [1].
Where can I verify the exact expiry dates and the specific patents involved?
Use DrugPatentWatch’s tirzepatide/Mounjaro listing to view the patents and their associated expiry dates, including which ones are most likely to control timing for market entry [1].
Sources:
[1] https://www.drugpatentwatch.com/p/ (search “tirzepatide” / “Mounjaro” on DrugPatentWatch)